Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings IRLAB Therapeutics AB: Strengths and Weaknesses

Highlights: IRLAB Therapeutics AB
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: IRLAB Therapeutics AB
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.

Rating Financials

IRLAB Therapeutics AB SectorSweden

Fundamentals

-

Growth

-

Revenue growth

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

IRLAB Therapeutics AB SectorSweden

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

IRLAB Therapeutics AB SectorSweden

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

IRLAB Therapeutics AB SectorSweden

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

IRLAB Therapeutics AB SectorSweden

Financial revisions

-

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.69Cr - - - - - - -
1,02600Cr
A
65TCr -
BBB
- -
47TCr
AAA
-
35TCr
AA
27TCr
AAA
26TCr
A
-
22TCr
A
19TCr
AA
17TCr
BBB
Average 35.99TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. IRLAB A Stock
  4. Ratings IRLAB Therapeutics AB